AbCellera Biologics (ABCL) Net Income towards Common Stockholders (2020 - 2026)

AbCellera Biologics has reported Net Income towards Common Stockholders for 7 years, with the latest figure at -$43.2 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 5.38% year-over-year to -$43.2 million; the trailing twelve-month figure through Mar 2026 stood at -$144.0 million (up 14.24% YoY), and the FY2025 full-year result was -$146.4 million, up 10.1% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$43.2 million, down from -$8.9 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $168.6 million in Q1 2022, with the low at -$57.1 million in Q3 2025.
• Historically, Net Income towards Common Stockholders has averaged -$20.0 million across 5 years, with a median of -$34.7 million in 2025.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders jumped 224.53% — and 2023, when it tumbled 349.93%.
• AbCellera Biologics' Net Income towards Common Stockholders stood at -$29.9 million in 2022, then sank by 57.73% to -$47.2 million in 2023, then rose by 27.44% to -$34.2 million in 2024, then surged by 73.85% to -$8.9 million in 2025, then tumbled by 382.56% to -$43.2 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$43.2 million (Q1 2026), -$8.9 million (Q4 2025), and -$57.1 million (Q3 2025), per Business Quant data.